Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy

The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahavi, David, AlDeghaither, Dalal, O’Connell, Allison, Weiner, Louis M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990127/
https://www.ncbi.nlm.nih.gov/pubmed/33928217
http://dx.doi.org/10.1093/abt/tby002
_version_ 1783669018934116352
author Zahavi, David
AlDeghaither, Dalal
O’Connell, Allison
Weiner, Louis M
author_facet Zahavi, David
AlDeghaither, Dalal
O’Connell, Allison
Weiner, Louis M
author_sort Zahavi, David
collection PubMed
description The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This review will summarize the process of ADCC, its important role in the efficacy of mAb therapy, how to measure it, and finally future strategies for antibody design that can take advantage of it to improve clinical performance.
format Online
Article
Text
id pubmed-7990127
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79901272021-04-28 Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy Zahavi, David AlDeghaither, Dalal O’Connell, Allison Weiner, Louis M Antib Ther Review The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This review will summarize the process of ADCC, its important role in the efficacy of mAb therapy, how to measure it, and finally future strategies for antibody design that can take advantage of it to improve clinical performance. Oxford University Press 2018-06-24 /pmc/articles/PMC7990127/ /pubmed/33928217 http://dx.doi.org/10.1093/abt/tby002 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Antibody Therapeutics. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review
Zahavi, David
AlDeghaither, Dalal
O’Connell, Allison
Weiner, Louis M
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
title Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
title_full Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
title_fullStr Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
title_full_unstemmed Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
title_short Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
title_sort enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990127/
https://www.ncbi.nlm.nih.gov/pubmed/33928217
http://dx.doi.org/10.1093/abt/tby002
work_keys_str_mv AT zahavidavid enhancingantibodydependentcellmediatedcytotoxicityastrategyforimprovingantibodybasedimmunotherapy
AT aldeghaitherdalal enhancingantibodydependentcellmediatedcytotoxicityastrategyforimprovingantibodybasedimmunotherapy
AT oconnellallison enhancingantibodydependentcellmediatedcytotoxicityastrategyforimprovingantibodybasedimmunotherapy
AT weinerlouism enhancingantibodydependentcellmediatedcytotoxicityastrategyforimprovingantibodybasedimmunotherapy

Ejemplares similares